NCT00479258View on ClinicalTrials.gov

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Inhaled insulin (Exubera)

Inhaled insulin with dose adjusted according to premeal blood glucose

DRUG

Subcutaneous Insulin (subject's prescribed)

Subcutaneous insulin with dose adjusted according to premeal blood glucose

Trial Locations (1)

14222

Pfizer Investigational Site, Buffalo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY